Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
FDA Oncology Update
FDA Oncology Update
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Read More
FDA Oncology Update
FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial
Read More
FDA Oncology Update
,
Breast Cancer
FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer
Read More
FDA Oncology Update
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
Read More
FDA Oncology Update
,
Lung Cancer
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Read More
FDA Oncology Update
Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma
Read More
FDA Oncology Update
,
Lung Cancer
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
FDA Oncology Update
,
Lung Cancer
Opdivo plus Yervoy and Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
FDA Oncology Update
,
Hepatocellular Carcinoma
Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma
Read More
FDA Oncology Update
,
Prostate Cancer
Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation
Read More
1
2
3
4
5
Page 2 of 13
Results 11 - 20 of 121